Teratogenic effects of thalidomide: Molecular mechanisms

Cellular and Molecular Life Sciences

Volumn 68, Issue 9, 2011, Pages 1569-1579

  Ito, Takumi ^a   Ando, Hideki ^a   Handa, Hiroshi ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Anti angiogenesis; Cereblon; Fibroblast growth factor 8; Oxidative stress; Teratogenicity; Thalidomide

Indexed keywords

BINDING PROTEIN; CEREBLON; DAMAGED DNA BINDING PROTEIN 1; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 8; LENALIDOMIDE; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR B; POMALIDOMIDE; PROTEIN KINASE B; THALIDOMIDE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BIRTH DEFECT; CHRONIC LYMPHATIC LEUKEMIA; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; LEPROSY; LIMB MALFORMATION; MAXIMUM PLASMA CONCENTRATION; MORNING SICKNESS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOMA; NEWBORN MORTALITY; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATIVE STRESS; PREGNANT WOMAN; RENDU OSLER WEBER DISEASE; REVIEW; SICKLE CELL ANEMIA; SOLID TUMOR; SPECIES DIFFERENCE; SPONTANEOUS ABORTION; TERATOGENESIS; TERATOGENICITY; TISSUE SPECIFICITY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; CHICK EMBRYO; FIBROBLAST GROWTH FACTOR 8; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PEPTIDE HYDROLASES; RABBITS; SPECIES SPECIFICITY; TERATOGENS; THALIDOMIDE; UBIQUITIN-PROTEIN LIGASES; ZEBRAFISH;

EID: 79958765360     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0619-9     Document Type: Review

References (93)

1. Franks ME, Macpherson GR, Figg WD (2004) Thalidomide. Lancet 363:1802-1811 (Pubitemid 38698386)
2. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322 (Pubitemid 38525287)
3. Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39:1489-1499 (Pubitemid 47031027)
4. Knobloch J, Ruther U (2008) Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 7:1121-1127 (Pubitemid 351749260)
5. Vargesson N (2009) Thalidomide-induced limb defects: resolving a 50-year-old puzzle. Bioessays 31:1327-1336
6. McBride WG (1977) Thalidomide embryopathy. Teratology 16:79-82
7. Lenz W (1988) A short history of thalidomide embryopathy. Teratology 38:203-215
8. Sheskin J (1965) Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303-306
9. Gutierrez-Rodriguez O (1984) Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum 27:1118-1121
10. Hamza MH (1986) Treatment of Behcet's disease with thalidomide. Clin Rheumatol 5:365-371
11. McCarthy DM, Kanfer EJ, Barrett AJ (1989) Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation. Biomed Pharmacother 43:693-697 (Pubitemid 20088544)
12. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, Santos GW (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055-1058
13. Atra E, Sato EI (1993) Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 11:487-493 (Pubitemid 23328811)
14. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, Schauf V, Kaplan G (1993) Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90:5974-5978 (Pubitemid 23191436)
15. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699-703
16. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680 (Pubitemid 23146134)
17. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085 (Pubitemid 24139577)
18. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
19. Zeldis JB, Williams BA, Thomas SD, Elsayed ME (1999) S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319-330
20. Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, Correa-Neto J, Delgadillo JL, Dutra MG, Felix T, Giraldo A, Juarez N, Lopez-Camelo JS, Nazer J, Orioli IM, Paz JE, Pessoto MA, Pina-Neto JM, Quadrelli R, Rittler M, Rueda S, Saltos M, Sanchez O, Schuler L (1996) Thalidomide, a current teratogen in South America. Teratology 54:273-277
21. Schuler-Faccini L, Soares RC, de Sousa AC, Maximino C, Luna E, Schwartz IV, Waldman C, Castilla EE (2007) New cases of thalidomide embryopathy in Brazil. Birth Defects Res A Clin Mol Teratol 79:671-672 (Pubitemid 47502794)
22. Hansen JM, Harris C (2004) A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway. Antioxid Redox Signal 6:1-14 (Pubitemid 38063971)
23. Parman T, Wiley MJ, Wells PG (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585
24. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (2009) Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci USA 106:8573-8578
25. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H (2010) Identification of a primary target of thalidomide teratogenicity. Science 327:1345-1350
26. Eriksson T, Bjorkman S, Roth B, Hoglund P (2000) Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol 52:807-817 (Pubitemid 30461914)
27. Braun AG, Harding FA, Weinreb SL (1986) Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol Appl Pharmacol 82:175-179 (Pubitemid 16146457)
28. Ando Y, Fuse E, Figg WD (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973 (Pubitemid 34633760)
29. Chen TL, Vogelsang GB, Petty BG, Brundrett RB, Noe DA, Santos GW, Colvin OM (1989) Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 17:402-405 (Pubitemid 19206582)
30. Chung F, Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Tingle M, Ching LM (2004) Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res 10:5949-5956 (Pubitemid 39180977)
31. Miller MT, Stromland K (1999) Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 60:306-321 (Pubitemid 30265249)
32. Mellin GW, Katzenstein M (1962) The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 267:1184-1192
33. Spouge D, Baird PA (1986) Imperforate anus in 700,000 consecutive liveborn infants. Am J Med Genet Suppl 2:151-161
34. Davis MC, Dahn RD, Shubin NH (2007) An autopodial-like pattern of Hox expression in the fins of a basal actinopterygian fish. Nature 447:473-476 (Pubitemid 46816741)
35. Tanaka M, Munsterberg A, Anderson WG, Prescott AR, Hazon N, Tickle C (2002) Fin development in a cartilaginous fish and the origin of vertebrate limbs. Nature 416:527-531 (Pubitemid 34288852)
36. Moon AM, Capecchi MR (2000) Fgf8 is required for outgrowth and patterning of the limbs. Nat Genet 26:455-459
37. Lewandoski M, Sun X, Martin GR (2000) Fgf8 signalling from the AER is essential for normal limb development. Nat Genet 26:460-463
38. Hansen JM, Gong SG, Philbert M, Harris C (2002) Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide. Dev Dyn 225:186-194
39. Brent RL (1964) Drug testing in animals for teratogenic effects. Thalidomide in the pregnant rat. J Pediatr 64:762-770
40. Kenyon BM, Browne F, D'Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971-978 (Pubitemid 27314772)
41. Fratta ID, Sigg EB, Maiorana K (1965) Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice. Toxicol Appl Pharmacol 7:268-286
42. Stephens TD (1988) Proposed mechanisms of action in thalidomide embryopathy. Teratology 38:229-239
43. Stephens TD, Fillmore BJ (2000) Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology 61:189-195
44. Stephens TD, Bunde CJ, Fillmore BJ (2000) Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59:1489-1499 (Pubitemid 30229881)
45. Parman T, Chen G, Wells PG (1998) Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis. J Biol Chem 273:25079-25088 (Pubitemid 28443265)
46. Wells PG, Winn LM (1996) Biochemical toxicology of chemical teratogenesis. Crit Rev Biochem Mol Biol 31:1-40 (Pubitemid 26076456)
47. Ohuchi H, Nakagawa T, Yamamoto A, Araga A, Ohata T, Ishimaru Y, Yoshioka H, Kuwana T, Nohno T, Yamasaki M, Itoh N, Noji S (1997) The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor. Development 124:2235-2244 (Pubitemid 27283244)
48. Knobloch J, Shaughnessy JD Jr, Ruther U (2007) Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 21:1410-1421 (Pubitemid 46684844)
49. Knobloch J, Schmitz I, Gotz K, Schulze-Osthoff K, Ruther U (2008) Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 28:529-538
50. Pizette S, Niswander L (1999) BMPs negatively regulate structure and function of the limb apical ectodermal ridge. Development 126:883-894 (Pubitemid 29141997)
51. Scherz PJ, Harfe BD, McMahon AP, Tabin CJ (2004) The limb bud Shh-Fgf feedback loop is terminated by expansion of former ZPA cells. Science 305:396-399 (Pubitemid 38938155)
52. Leslie NR, Downes CP (2004) PTEN function: how normal cells control it and tumour cells lose it. Biochem J 382:1-11 (Pubitemid 39141560)
53. Pajni-Underwood S, Wilson CP, Elder C, Mishina Y, Lewandoski M (2007) BMP signals control limb bud interdigital programmed cell death by regulating FGF signaling. Development 134:2359-2368 (Pubitemid 47010024)
54. Andela VB, Sheu TJ, Puzas EJ, Schwarz EM, O'Keefe RJ, Rosier RN (2002) Malignant reversion of a human osteosarcoma cell line, Saos-2, by inhibition of NFkappaB. Biochem Biophys Res Commun 297:237-241 (Pubitemid 35216160)
55. Grotewold L, Ruther U (2002) The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 21:966-975 (Pubitemid 34206169)
56. Beurel E, Jope RS (2006) The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79:173-189 (Pubitemid 44331500)
57. Sauer H, Gunther J, Hescheler J, Wartenberg M (2000) Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am J Pathol 156:151-158 (Pubitemid 30644447)
58. Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T (2005) Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106:125-134 (Pubitemid 40967183)
59. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834 (Pubitemid 28305265)
60. Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Muller G, Ching LM (2003) Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res 9:1680-1688 (Pubitemid 36554591)
61. Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD (2003) Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 63:3189-3194 (Pubitemid 36735871)
62. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF (1995) Stages of embryonic development of the zebrafish. Dev Dyn 203:253-310
63. Grandel H, Schulte-Merker S (1998) The development of the paired fins in the zebrafish (Danio rerio). Mech Dev 79:99-120 (Pubitemid 29038026)
64. Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Breant C, Mathivet T, Larrivee B, Thomas JL, Arthur HM, Westermann CJ, Disch F, Mager JJ, Snijder RJ, Eichmann A, Mummery CL (2010) Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 16:420-428
65. Sakamoto S, Kabe Y, Hatakeyama M, Yamaguchi Y, Handa H (2009) Development and application of high-performance affinity beads: toward chemical biology and drug discovery. Chem Rec 9:66-85
66. Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, Hiramoto M, Aizawa S, Hatakeyama M, Ohba R, Hatori H, Yoshikawa T, Suzuki F, Oomori A, Tanaka H, Kawaguchi H, Watanabe H, Handa H (2000) High-performance affinity beads for identifying drug receptors. Nat Biotechnol 18:877-881 (Pubitemid 30640915)
67. Nishio K, Masaike Y, Ikeda M, Narimatsu H, Gokon N, Tsubouchi S, Hatakeyama M, Sakamoto S, Hanyu N, Sandhu A, Kawaguchi H, Abe M, Handa H (2008) Development of novel magnetic nano-carriers for high-performance affinity purification. Colloids Surf B Biointerfaces 64:162-169
68. Higgins JJ, Pucilowska J, Lombardi RQ, Rooney JP (2004) A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 63:1927-1931 (Pubitemid 39532392)
69. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N (2006) Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443:590-593 (Pubitemid 44527296)
70. Jo S, Lee KH, Song S, Jung YK, Park CS (2005) Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J Neurochem 94:1212-1224 (Pubitemid 41232577)
71. Hohberger B, Enz R (2009) Cereblon is expressed in the retina and binds to voltage-gated chloride channels. FEBS Lett 583:633-637
72. Wittschieben BO, Wood RD (2003) DDB complexities. DNA Repair (Amst) 2:1065-1069 (Pubitemid 37088165)
73. Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6:9-20 (Pubitemid 40064895)
74. Groisman R, Polanowska J, Kuraoka I, Sawada J, Saijo M, Drapkin R, Kisselev AF, Tanaka K, Nakatani Y (2003) The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 113:357-367 (Pubitemid 36556117)
75. Lee J, Zhou P (2007) DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell 26:775-780 (Pubitemid 46921011)
76. Pickart CM (2004) Back to the future with ubiquitin. Cell 116:181-190
77. Sugasawa K, Okuda Y, Saijo M, Nishi R, Matsuda N, Chu G, Mori T, Iwai S, Tanaka K, Hanaoka F (2005) UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell 121:387-400 (Pubitemid 40692299)
78. Groisman R, Kuraoka I, Chevallier O, Gaye N, Magnaldo T, Tanaka K, Kisselev AF, Harel-Bellan A, Nakatani Y (2006) CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome. Genes Dev 20:1429-1434 (Pubitemid 43830649)
79. Lieschke GJ, Currie PD (2007) Animal models of human disease: zebrafish swim into view. Nat Rev Genet 8:353-367 (Pubitemid 46625809)
80. Nasevicius A, Ekker SC (2000) Effective targeted gene 'knockdown' in zebrafish. Nat Genet 26:216-220
81. Lee KJ, Lee KM, Jo S, Kang KW, Park CS (2010) Induction of cereblon by NF-E2-related factor 2 in neuroblastoma cells exposed to hypoxia-reoxygenation. Biochem Biophys Res Commun 399:711-715
82. Kang KW, Lee SJ, Kim SG (2005) Molecular mechanism of nrf2 activation by oxidative stress. Antioxid Redox Signal 7:1664-1673 (Pubitemid 41768000)
83. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 101:6062-6067 (Pubitemid 38520528)
84. Field HA, Dong PD, Beis D, Stainier DY (2003) Formation of the digestive system in zebrafish. II. Pancreas morphogenesis. Dev Biol 261:197-208
85. Knobloch J, Reimann K, Klotz LO, Ruther U (2008) Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense. Mol Pharm 5:1138-1144
86. Janer G, Verhoef A, Gilsing HD, Piersma AH (2008) Use of the rat postimplantation embryo culture to assess the embryotoxic potency within a chemical category and to identify toxic metabolites. Toxicol In Vitro 22:1797-1805
87. Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, Hatakeyama M, Yamaguchi Y, Takahashi T, Kizaki M, Handa H (2006) A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol 70:1832-1839
88. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557 (Pubitemid 40204668)
89. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC (2008) Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26:2519-2525
90. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24:5343-5349 (Pubitemid 46623164)
91. Chanan-Khan AA, Cheson BD (2008) Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26:1544-1552
92. Xu Y, Li J, Ferguson GD, Mercurio F, Khambatta G, Morrison L, Lopez-Girona A, Corral LG, Webb DR, Bennett BL, Xie W (2009) Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114:338-345
93. Aragon-Ching JB, Li H, Gardner ER, Figg WD (2007) Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov 2:167-174 (Pubitemid 46952433)